Recently, the Circulation sub-journal (Circulation: Cardiovascular Quality and Outcomes, Chinese Academy of Sciences Division 2021 Upgraded, Medical First Division Top) published online an article entitled "Efficacy and Safety of Chinese Herbal Medicine Compared With Losartan for Mild Essential", the official journal of the American Heart Association AHA.
Hypertension: A Randomized, Multicenter, Double-Blind, Noninferiority Trial" clinical research paper, Chinese medicine treatment of essential hypertension adds high-quality clinical evidence, and the results have been recognized by international authoritative journals
There are about 270 million people with hypertension in China.
Hypertension is a major risk factor for major diseases such as cardiovascular and cerebrovascular diseases and chronic kidney disease
Although there are a variety of antihypertensive drugs, the treatment rate and control rate of hypertensive patients in China are still low
Because Chinese medicine can improve clinical symptoms and control blood pressure, many hypertensive patients are willing to seek Chinese medicine treatment
However, there is still a lack of high-quality clinical evidence for the treatment of hypertension by traditional Chinese medicine, and it has not been widely recognized by domestic and foreign counterparts
In response to the above research problems, the Special Committee of Drug Clinical Evaluation and Research of China Traditional Chinese Medicine Association established a multidisciplinary research team of traditional Chinese medicine theory-heart-brain traditional Chinese and western medicine clinical-methodology.
Vice Chairman of the Encephalopathy Drug Research Committee, Professor Gao Ying of Dongzhimen Hospital of Beijing University of Traditional Chinese Medicine, Chairman of the Cardiovascular Drug Research Committee of China Traditional Chinese Medicine Association, Professor Wu Zonggui of Shanghai Changzheng Hospital, and jointly led by Xuanwu Hospital of Capital Medical University and Beijing Chaoyang The hospital and the China-Japan Friendship Hospital of the Ministry of Health and other 17 national Chinese and Western medicine clinical research institutions participated together, and the Beijing Kangpaite Drug Clinical Research and Evaluation Center was responsible for the implementation.
A randomized, double-blind, double-dummy, multicenter clinical study in patients with essential hypertension (grade 1)
This clinical study of Songling Xuemaikang in the treatment of first-degree hypertension is based on the CER study of more than 5,000 cases to select a specific target group, and under the theoretical guidance of the combination of blood and blood and combined treatment of heart and brain, the clinical research plan of the drug is formulated.
It aims to explore the unique clinical value of Songling Xuemaikang through scientific design and rigorous quality control
A total of 628 patients with grade 1 hypertension were included in this study, who were randomly divided into the Songling Xuemaikang group (314 cases) and the losartan group (314 cases) according to the ratio of 1:1, and received 8 weeks of treatment respectively
The results showed that Songling Xuemaikang was non-inferior to losartan in reducing diastolic blood pressure, and both had similar effects in reducing systolic blood pressure and improving 24-hour ambulatory blood pressure-related indicators; and in reducing serum total cholesterol and improving hypertension symptoms ( Especially in terms of liver-yang hyperactivity-related symptoms), Songling Xuemaikang was significantly better than losartan